spironolactone has been researched along with Depression in 14 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double blind placebo controlled randomized cross over study was conducted to assess the response to spironolactone by patients suffering from 'Premenstrual Syndrome'." | 9.07 | Premenstrual syndrome and spironolactone. ( Burnet, RB; Easterbrook, EG; McKinnon, RA; Radden, HS, 1991) |
| " The addition of spironolactone to her previous medications controlled and normalized hypertension, hypokalemia, and hormonal abnormalities within 4 months." | 7.76 | Resistant hypertension in an aged woman presenting with clinical features simulating ectopic ACTH syndrome--response to spironolactone--. ( Harada, E; Mizuno, Y; Morikawa, Y; Nakagawa, H; Saito, Y; Semba, F; Yasue, H; Yoshimura, M, 2010) |
| "Treatment of Preserved Cardiac Function with an Aldosterone Antagonist (TOPCAT) is an ongoing randomized controlled trial of spironolactone versus placebo for heart failure with preserved ejection fraction (HFpEF)." | 5.17 | Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. ( Anand, IS; Boineau, R; Clausell, N; Desai, AS; Diaz, R; Fleg, JL; Gordeev, I; Harty, B; Heitner, JF; Kim, HY; Kobulia, B; Lewis, EF; Li, R; Markov, V; O'Meara, E; Pfeffer, MA; Pitt, B; Shaburishvili, T; Shah, SJ; Solomon, SD; Sweitzer, NK, 2013) |
| "A double blind placebo controlled randomized cross over study was conducted to assess the response to spironolactone by patients suffering from 'Premenstrual Syndrome'." | 5.07 | Premenstrual syndrome and spironolactone. ( Burnet, RB; Easterbrook, EG; McKinnon, RA; Radden, HS, 1991) |
| " The addition of spironolactone to her previous medications controlled and normalized hypertension, hypokalemia, and hormonal abnormalities within 4 months." | 3.76 | Resistant hypertension in an aged woman presenting with clinical features simulating ectopic ACTH syndrome--response to spironolactone--. ( Harada, E; Mizuno, Y; Morikawa, Y; Nakagawa, H; Saito, Y; Semba, F; Yasue, H; Yoshimura, M, 2010) |
| " Subsequently, gynecomastia developed as a side effect of spironolactone and digoxin treatment." | 3.75 | [A mourning case that referred with sexual identity disorder secondary to a general medical condition]. ( Ceri, O; Koçak, OM; Soykan, A; Tatlidil, E; Yilmaz, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Ragmanauskaite, L | 1 |
| Kahn, B | 1 |
| Ly, B | 1 |
| Yeung, H | 1 |
| Balogh, DB | 1 |
| Molnar, A | 1 |
| Hosszu, A | 1 |
| Lakat, T | 1 |
| Hodrea, J | 1 |
| Szabo, AJ | 1 |
| Lenart, L | 1 |
| Fekete, A | 1 |
| Sbolli, M | 1 |
| O'Connor, CM | 1 |
| Hamo, CE | 1 |
| Heitner, JF | 2 |
| Pfeffer, MA | 2 |
| Kim, HY | 2 |
| Kenwood, CT | 1 |
| Assmann, SF | 1 |
| Solomon, SD | 2 |
| Boineau, R | 2 |
| Fleg, JL | 2 |
| Spertus, JA | 1 |
| Lewis, EF | 2 |
| Jing, L | 1 |
| Duan, TT | 1 |
| Tian, M | 1 |
| Yuan, Q | 1 |
| Tan, JW | 1 |
| Zhu, YY | 1 |
| Ding, ZY | 1 |
| Cao, J | 1 |
| Yang, YX | 1 |
| Zhang, X | 1 |
| Mao, RR | 1 |
| Richter-Levin, G | 1 |
| Zhou, QX | 1 |
| Xu, L | 1 |
| Yilmaz, A | 1 |
| Ceri, O | 1 |
| Tatlidil, E | 1 |
| Koçak, OM | 1 |
| Soykan, A | 1 |
| Harada, E | 1 |
| Yasue, H | 1 |
| Mizuno, Y | 1 |
| Morikawa, Y | 1 |
| Nakagawa, H | 1 |
| Semba, F | 1 |
| Yoshimura, M | 1 |
| Saito, Y | 1 |
| Wu, TC | 1 |
| Chen, HT | 1 |
| Chang, HY | 1 |
| Yang, CY | 1 |
| Hsiao, MC | 1 |
| Cheng, ML | 1 |
| Chen, JC | 1 |
| Shah, SJ | 1 |
| Sweitzer, NK | 1 |
| Anand, IS | 1 |
| Harty, B | 1 |
| Clausell, N | 1 |
| Desai, AS | 1 |
| Diaz, R | 1 |
| Gordeev, I | 1 |
| Markov, V | 1 |
| O'Meara, E | 1 |
| Kobulia, B | 1 |
| Shaburishvili, T | 1 |
| Pitt, B | 1 |
| Li, R | 1 |
| Taylor, JW | 1 |
| Zweifler, AJ | 1 |
| Esler, M | 1 |
| Burnet, RB | 1 |
| Radden, HS | 1 |
| Easterbrook, EG | 1 |
| McKinnon, RA | 1 |
| Rawlins, MD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302] | Phase 3 | 3,445 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.09 |
| Spironolactone | 0.05 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 4.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 3.1 |
| Spironolactone | 2.8 |
Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.2 |
| Spironolactone | 5.5 |
Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 102.33 |
| Spironolactone | 102.26 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 7.8 |
| Spironolactone | 7.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.6 |
| Spironolactone | 5.9 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 5.6 |
| Spironolactone | 5.1 |
First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 2.2 |
| Spironolactone | 3.2 |
First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.4 |
| Spironolactone | 1.4 |
Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mL/min/1.73m2 (Least Squares Mean) |
|---|---|
| Placebo | 67.50 |
| Spironolactone | 65.20 |
First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 20.0 |
| Spironolactone | 18.8 |
First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 3.8 |
First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.2 |
First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.7 |
| Spironolactone | 0.7 |
Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Spironolactone | 4.49 |
"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Spironolactone | 1.2 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 65.9 |
| Spironolactone | 66.4 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 63.1 |
| Spironolactone | 64.4 |
Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 1.11 |
| Spironolactone | 1.17 |
Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 140.95 |
| Spironolactone | 140.33 |
First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 8.3 |
| Spironolactone | 6.8 |
2 reviews available for spironolactone and Depression
| Article | Year |
|---|---|
Acne and the Lesbian, Gay, Bisexual, or Transgender Teenager.
Topics: Abnormalities, Drug-Induced; Acne Vulgaris; Adolescent; Androgen Antagonists; Androgens; Contracepti | 2020 |
Variability in response to drugs.
Topics: Acute Disease; Acylation; Chlorthalidone; Chronic Disease; Depression; Diazoxide; Digoxin; Dose-Resp | 1974 |
3 trials available for spironolactone and Depression
| Article | Year |
|---|---|
Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial.
Topics: Aged; Aged, 80 and over; Comorbidity; Depression; Female; Heart Failure; Humans; Life Style; Logisti | 2015 |
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.
Topics: Aged; Argentina; Comorbidity; Depression; Double-Blind Method; Electrocardiography; Female; Heart Fa | 2013 |
Premenstrual syndrome and spironolactone.
Topics: Androgens; Depression; Double-Blind Method; Female; Humans; Premenstrual Syndrome; Spironolactone | 1991 |
9 other studies available for spironolactone and Depression
| Article | Year |
|---|---|
Antidepressant effect in diabetes-associated depression: A novel potential of RAAS inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antidepressive Agents; Antihypertensive Agents; B | 2020 |
Aldosterone: Behind the Scenes of Depression and Heart Failure?
Topics: Aldosterone; Depression; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolacto | 2020 |
Despair-associated memory requires a slow-onset CA1 long-term potentiation with unique underlying mechanisms.
Topics: Animals; CA1 Region, Hippocampal; Corticosterone; Depression; Dizocilpine Maleate; Excitatory Amino | 2015 |
[A mourning case that referred with sexual identity disorder secondary to a general medical condition].
Topics: Bereavement; Depression; Digoxin; Erectile Dysfunction; Female; Gender Identity; Gynecomastia; Human | 2009 |
Resistant hypertension in an aged woman presenting with clinical features simulating ectopic ACTH syndrome--response to spironolactone--.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Ag | 2010 |
Mineralocorticoid receptor antagonist spironolactone prevents chronic corticosterone induced depression-like behavior.
Topics: Animals; Behavior, Animal; Corticosterone; Depression; Hippocampus; Hydroxyindoleacetic Acid; Hypoth | 2013 |
Mental symptoms and electrolyte imbalance.
Topics: Aged; Chlorine; Cognition Disorders; Confusion; Depression; Diuretics; Female; Humans; Hyponatremia; | 1979 |
Drugs for hypertension.
Topics: Antihypertensive Agents; Benzothiadiazines; Clonidine; Depression; Diuretics; Drug Combinations; Dru | 1977 |
Factors influencing the choice of antihypertensive agents.
Topics: Age Factors; Aldosterone; Cerebrovascular Disorders; Clonidine; Depression; Diabetes Complications; | 1976 |